FRA:ZEG - GB0009895292 - Common Stock
The current stock price of ZEG.DE is 139.5 EUR. In the past month the price increased by 10.8%. In the past year, price decreased by -6.97%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 45.04 | 588.70B | ||
1LLY.MI | ELI LILLY & CO | 44.97 | 587.85B | ||
JNJ.DE | JOHNSON & JOHNSON | 17.85 | 367.61B | ||
1JNJ.MI | JOHNSON & JOHNSON | 17.65 | 365.97B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.75 | 250.06B | ||
NOT.DE | NOVARTIS AG-REG | 14.84 | 214.61B | ||
NOV.DE | NOVO NORDISK A/S-B | 14.08 | 209.02B | ||
SAN.PA | SANOFI | 10.53 | 193.90B | ||
SNW.DE | SANOFI | 10.53 | 193.90B | ||
1SAN.MI | SANOFI | 10.52 | 193.75B | ||
6MK.DE | MERCK & CO. INC. | 10.96 | 180.09B | ||
PFE.DE | PFIZER INC | 7.25 | 119.57B |
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
ASTRAZENECA PLC
1 Francis Crick Avenue, Cambridge Biomedical Campus
CAMBRIDGE CAMBRIDGESHIRE GB
Employees: 94300
Phone: 442073045000
The current stock price of ZEG.DE is 139.5 EUR. The price decreased by -0.92% in the last trading session.
The exchange symbol of ASTRAZENECA PLC is ZEG and it is listed on the Deutsche Boerse Ag exchange.
ZEG.DE stock is listed on the Deutsche Boerse Ag exchange.
34 analysts have analysed ZEG.DE and the average price target is 157.04 EUR. This implies a price increase of 12.57% is expected in the next year compared to the current price of 139.5. Check the ASTRAZENECA PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ASTRAZENECA PLC (ZEG.DE) has a market capitalization of 432.52B EUR. This makes ZEG.DE a Mega Cap stock.
ASTRAZENECA PLC (ZEG.DE) currently has 94300 employees.
ASTRAZENECA PLC (ZEG.DE) has a support level at 138.03 and a resistance level at 143.6. Check the full technical report for a detailed analysis of ZEG.DE support and resistance levels.
The Revenue of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 9.37% in the next year. Check the estimates tab for more information on the ZEG.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ASTRAZENECA PLC (ZEG.DE) has a dividend yield of 2.01%. The yearly dividend amount is currently 2.55. Check the full fundamental report for a detailed analysis of ZEG.DE dividend history, reliability and sustainability.
ASTRAZENECA PLC (ZEG.DE) will report earnings on 2025-11-06, before the market open.
The PE ratio for ASTRAZENECA PLC (ZEG.DE) is 18.48. This is based on the reported non-GAAP earnings per share of 7.55 and the current share price of 139.5 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ZEG.DE.
ChartMill assigns a technical rating of 7 / 10 to ZEG.DE. When comparing the yearly performance of all stocks, ZEG.DE is a bad performer in the overall market: 64.62% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE. While ZEG.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months ZEG.DE reported a non-GAAP Earnings per Share(EPS) of 7.55. The EPS increased by 22.3% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 14.68% | ||
ROA | 7.38% | ||
ROE | 18.55% | ||
Debt/Equity | 0.63 |
34 analysts have analysed ZEG.DE and the average price target is 157.04 EUR. This implies a price increase of 12.57% is expected in the next year compared to the current price of 139.5.
For the next year, analysts expect an EPS growth of 13.69% and a revenue growth 9.37% for ZEG.DE